Medical Policy Revision: Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Disease and Venous Thromboembolic Disease

Effective June 18, 2018, Horizon Blue Cross Blue Shield of New Jersey will change the way we consider certain professional claims for the use of homocysteine testing.

We encourage you to visit our Medical Policy Manual to review the guidelines of our medical policy, Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Disease and Venous Thromboembolic Disease, which identify when the use of homocysteine testing is considered medically necessary.

Based on the guidelines included in our medical policy, Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Disease and Venous Thromboembolic Disease AND the submitted diagnosis code(s):

• CPT^® code 83090 submitted on claims for services provided on and after June 18, 2018 may be denied as an experimental/investigational service.

Unless Horizon BCBSNJ gives written notice that all or part of the above changes have been cancelled or postponed, the changes will be applied to claims for dates of service on and after June 18, 2018.

CPT^® is a registered mark of the American Medical Association.